Search Results
The product title you are looking for is no longer available. Other similar products that may interest you are listed below:
|
Results for 'Commercial Insight: Targeted Therapy Cancer Brands' |
|
|
| Title | Publication Date | Price | Relevance |
|---|---|---|---|
| Pipeline Insight: Biologic Targeted Cancer Therapies Next generation jostles for market position |
Dec 2009 | £7,210 | 100% |
| Lung Cancer Therapeutics Market Outlook and Pipeline Analysis | Nov 2009 | £945 | 96% |
| Stakeholder Insight: Supportive Care in Cancer Treatment Some first-generation products proving difficult to dislodge |
Oct 2006 | £8,365 | 93% |
| The Cancer Market Outlook to 2016 Healthcare |
Jun 2011 | £2,425 | 91% |
| Gastric Cancer Drug Discoveries what the future holds |
Mar 2011 | £1,495 | 90% |
| Innovations in Cancer Novel Therapeutics, New Diagnostics and Future R&D Strategies |
Feb 2007 | £1,820 | 88% |
| Stakeholder Insight: Gastric Cancer | Sep 2010 | £9,615 | 88% |
| Stakeholder Insight: Chronic Leukemias Is there room left for improvement? |
Nov 2008 | £8,365 | 84% |
| Top 10 Healthcare Trends in 2011 | Mar 2011 | £2,215 | 81% |
| Mylan Inc.: PharmaVitae Profile | Jan 2010 | £3,605 | 80% |
| Stakeholder Opinions: Novel Therapeutic Approaches in Cardiovascular Medicine Lack of Market Prospects for Biologics Expose An Opportunity for Cell and Gene Therapies |
Jul 2008 | £4,805 | 80% |
| Drug Delivery Systems US Market Outlook, Advances for Pharma, Biotech & Medical Devices |
Sep 2006 | £1,450 | 78% |
| Radiation Therapy Equipment | Oct 2010 | £2,845 | 76% |
| The Global Pain Therapeutics Market 4th Edition: Market Trends & R&D Insights |
Nov 2010 | £1,105 | 75% |
| Colorectal Cancer Drug Futures | Oct 2010 | £1,495 | 75% |
| Top Companies and Products in the RNA/DNA Therapy Products Market Forecasts: The Challenge Of Turning Technology Into Therapy |
Jul 2007 | £1,999 | 75% |
| Pipeline Insight: Breakthrough Pain Fast-acting players will capture majority market share |
Nov 2006 | £7,210 | 73% |
| Renal Cell Carcinoma Cancer Drug Futures | Jan 2012 | £1,495 | 73% |
| Companion Biomarkers in Drug Development | Apr 2009 | £2,150 | 72% |
| Pipeline and Commercial Insight: Osteoporosis Novel agents to battle for payer acceptance |
Jul 2009 | £9,615 | 71% |
| Commercial Insight: Infectious Diseases Overview | Dec 2007 | £9,615 | 68% |
| Drug Delivery Technologies: Players, products & prospects to 2018 | Jun 2009 | £1,795 | 67% |
| Orphan Drugs Strategic Approaches for the Industry | Jan 2012 | £695 | 63% |
| Anticoagulants | Sep 2010 | £2,845 | 59% |
| Nanotechnology: Players, products & prospects to 2018 (Volume II) | Jan 2012 | £595 | 55% |
| The Indian Pharmaceutical Industry New strategies in a changing world |
Jan 2012 | £995 | 46% |
- Results 1 - 26 of 26
-
-
- 1
-
-
